Race Oncology (RAC) investor relations material

Mechanism of action and scientific insights

• (E,E)-bisantrene binds and stabilizes G-quadruplex (G4) structures in DNA and RNA, regulating genes critical for cancer growth, notably MYC, and making cancer cells more sensitive to other drugs.

• G4 structures act as regulatory switches for cell growth, division, genome stability, and epigenetic modifications.

• Bisantrene's anticancer effects include inhibiting DNA/RNA synthesis, angiogenesis, telomerase, topoisomerase II, and MYC expression, while also stimulating immune responses and synergizing with other drugs.

• Experiments confirm (E,E)-bisantrene is both a DNA and RNA G4 stabilizer, explaining its broad anticancer activities and enabling biomarker development.

MYC as a cancer target

• MYC is a master regulator of 2,000–4,000 genes, driving cell growth, division, and malignancy, but remains undruggable with no direct inhibitors in pharma pipelines.

• Elevated MYC activity is present in ~70% of all malignancies, with significant prevalence across major cancer types.

• MYC upregulation arises from gene amplification, signaling pathway mutations, epigenetic deregulation, and mRNA/protein stability changes.

• MYC drives all hallmarks of cancer, including uncontrolled proliferation, angiogenesis, metabolism, genomic instability, and drug resistance.

Commercial and investor relevance

• Understanding the mechanism of action (MOA) enables identification of optimal cancer types and drug combinations, reduces risk, and supports biomarker development.

• A well-defined MOA increases the probability of successful partnerships or licensing, as pharma partners expect clarity on new assets.